NPA Internal Review Sparked Suit Against Board Members, Ongoing Changes
This article was originally published in The Rose Sheet
A review launched after NPA's former CFO filed a wrongful termination complaint in November has invalidated the allegations, but has "also shown that there was some governance that needed to change," says Executive Director and CEO Daniel Fabricant.
You may also be interested in...
In lawsuits pending in DC District Court, former NPA CFO Brent Weickert claims he was wrongfully terminated after raising concerns with the trade group's board about CEO Daniel Fabricant's conduct, while NPA is suing to remove board members who allegedly conspired with Weickert to oust Fabricant and serve their own personal interests.
A proposed change would have removed the requirement that retail members have stores and that 75% of their sales come from natural foods, supplements and related items. But NPA members approved five bylaw amendments to simplify the process of voting for board members.
FDA approved sNDAs from GlaxoSmithKline for diclofenac-containing Voltaren Arthritis Pain for the temporary relief of arthritis pain and from Alcon for Pataday olopatadine drops at 0.2% concentration for once-daily use temporary relief of itchy eyes due to pollen, ragweed, grass, animal hair or dander and 0.1% for twice-daily use for the same indications plus redness relief.